XSHE
000813
Market cap999mUSD
Oct 09, Last price
3.26CNY
1D
2.19%
1Q
0.93%
Jan 2017
-66.11%
Name
Dezhan Healthcare Co Ltd
Chart & performance
P/E
—
P/S
17.23
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.96%
Rev. gr., 5y
-16.25%
Revenues
397m
-14.94%
Net income
-345m
L+1,592.15%
CFO
5m
P
Dividend
Jun 01, 20210.21 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dezhan Healthcare Company Limited operates primarily within the Chinese market, specializing in the research, development, manufacturing, and distribution of pharmaceutical products, with a particular focus on cardiovascular and cerebrovascular medications. The company's product range also extends to include oncology drugs, a variety of health and wellness products, functional beverages, and ecological water. Established in 1998, the firm maintains its headquarters in Urumqi, China.
Key people
Ling Wu
Chief Financial Officer · since 2025
Ye Liu
Chief Scientific Officer · since 2023
Deputy General Manager, Secretary of the Board · since 2023
Jinghong Zhang
Executive Deputy General Manager · since 2025
Peng Fu
Director · since 2025
Feng Han
Director · since 2022
Zhongying Li
Director · since 2023
Wei Liu
Co-Chairman of the Board, General Manager · since 2021
Zheming Wei
Chairman of the Board · since 2025
Independent Director · since 2025
Bin Wu
Independent Director · since 2021
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||